Copiktra (duvelisib): Drug Safety Communication – FDA Warns about Possible Increased Risk of Death and Serious Side Effects

FDA is warning that results from a clinical trial show a possible increased risk of death with Copiktra (duvelisib) compared to another medicine to treat a chronic blood cancer.
Tags: No tags

Comments are closed.